Global and China Osteoporosis Drugs Market, By Drug Type (Bisphosphonates (Alendronate, Risedronate, Ibandronate, Zoledronic Acid, Others), Calcitonin, Hormone Therapy, Selective Estrogen Receptor Modulators (SERMs), Parathyroid Hormone-Related Protein (P

Global and China Osteoporosis Drugs Market, By Drug Type (Bisphosphonates (Alendronate, Risedronate, Ibandronate, Zoledronic Acid, Others), Calcitonin, Hormone Therapy, Selective Estrogen Receptor Modulators (SERMs), Parathyroid Hormone-Related Protein (PTHrP) Analog, Rank Ligand (RANKL) Inhibitor), By Route of Administration (Oral, Injectable, Others), By Distribution Channel (Hospitals Pharmacies, Online Pharmacies, Retail Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, China, Middle East & Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Osteoporosis is characterized by reduction in the density and quality of bones that often result in broken bones in the wrist, hip, and spine. Various factors responsible for osteoporosis include, genetic factors, low intake of calcium, magnesium, and vitamin D, eating disorders such as anorexia, inactivity and immobility, and excessive alcohol intake. Increasing approvals and launches of novel osteoporosis drugs along with increasing prevalence of osteoporasis is expected to significantly drive the osteoporosis treatment market growth over forecast period.
Key features of the study:
This report provides in-depth analysis of the Global and China Osteoporosis Drugs Market and provides market size (US$ Billion) and compound annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategy adopted by key players
It profiles key players in the Global and China Osteoporosis Drugs Market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include, Merck & Co., Eli Lilly, Procter & Gamble, Enzo Biochem, Inc., Sanofi-Aventis, Novartis, Wyeth, Roche, GlaxoSmithKline, UCB, Amgen, BeiGene Co., Ltd., Bone Biologics, Teijin Pharma Limited, JHL Biotech Inc., Keros Therapeutics, and Taro Pharmaceuticals Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
The Global and China Osteoporosis Drugs Market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Global and China Osteoporosis Drugs Market
Detailed Segmentation:
Global and China Osteoporosis Drugs Market, By Drug Type:
Bisphosphonates
Alendronate
Risedronate
Ibandronate
Zoledronic Acid
Others
Calcitonin
Hormone Therapy
Selective Estrogen Receptor Modulators (SERMs)
Parathyroid Hormone-Related Protein (PTHrP) Analog
Rank Ligand (RANKL) Inhibitor
Global and China Osteoporosis Drugs Market, By Route of Administration:
Oral
Injectable
Others
Global and China Osteoporosis Drugs Market, By Distribution Channel:
Hospitals Pharmacies
Online Pharmacies
Retail Pharmacies
Global and China Osteoporosis Drugs Market, By Region:
North America
By Drug Type:
Bisphosphonates
Alendronate
Risedronate
Ibandronate
Zoledronic Acid
Others
Calcitonin
Hormone Therapy
Selective Estrogen Receptor Modulators (SERMs)
Parathyroid Hormone-Related Protein (PTHrP) Analog
Rank Ligand (RANKL) Inhibitor
By Route of Administration
Oral
Injectable
Others
By Distribution Channel
Hospitals Pharmacies
Online Pharmacies
Retail Pharmacies
By Country
U.S.
Canada
Latin America
By Drug Type:
Bisphosphonates
Alendronate
Risedronate
Ibandronate
Zoledronic Acid
Others
Calcitonin
Hormone Therapy
Selective Estrogen Receptor Modulators (SERMs)
Parathyroid Hormone-Related Protein (PTHrP) Analog
Rank Ligand (RANKL) Inhibitor
By Route of Administration
Oral
Injectable
Others
By Distribution Channel
Hospitals Pharmacies
Online Pharmacies
Retail Pharmacies
By Country
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Drug Type:
Bisphosphonates
Alendronate
Risedronate
Ibandronate
Zoledronic Acid
Others
Calcitonin
Hormone Therapy
Selective Estrogen Receptor Modulators (SERMs)
Parathyroid Hormone-Related Protein (PTHrP) Analog
Rank Ligand (RANKL) Inhibitor
By Route of Administration
Oral
Injectable
Others
By Distribution Channel
Hospitals Pharmacies
Online Pharmacies
Retail Pharmacies
By Country
U.K.
Germany
France
Spain
Italy
Russia
Rest of Europe
Asia Pacific
By Drug Type:
Bisphosphonates
Alendronate
Risedronate
Ibandronate
Zoledronic Acid
Others
Calcitonin
Hormone Therapy
Selective Estrogen Receptor Modulators (SERMs)
Parathyroid Hormone-Related Protein (PTHrP) Analog
Rank Ligand (RANKL) Inhibitor
By Route of Administration
Oral
Injectable
Others
By Distribution Channel
Hospitals Pharmacies
Online Pharmacies
Retail Pharmacies
By Country
Japan
India
Australia
South Korea
ASEAN
Rest of Asia Pacific
China
By Drug Type:
Bisphosphonates
Alendronate
Risedronate
Ibandronate
Zoledronic Acid
Others
Calcitonin
Hormone Therapy
Selective Estrogen Receptor Modulators (SERMs)
Parathyroid Hormone-Related Protein (PTHrP) Analog
Rank Ligand (RANKL) Inhibitor
By Route of Administration
Oral
Injectable
Others
By Distribution Channel
Hospitals Pharmacies
Online Pharmacies
Retail Pharmacies
Middle East
By Drug Type:
Bisphosphonates
Alendronate
Risedronate
Ibandronate
Zoledronic Acid
Others
Calcitonin
Hormone Therapy
Selective Estrogen Receptor Modulators (SERMs)
Parathyroid Hormone-Related Protein (PTHrP) Analog
Rank Ligand (RANKL) Inhibitor
By Route of Administration
Oral
Injectable
Others
By Distribution Channel
Hospitals Pharmacies
Online Pharmacies
Retail Pharmacies
By Country
GCC Countries
Israel
Rest of Middle East
Africa
By Drug Type:
Bisphosphonates
Alendronate
Risedronate
Ibandronate
Zoledronic Acid
Others
Calcitonin
Hormone Therapy
Selective Estrogen Receptor Modulators (SERMs)
Parathyroid Hormone-Related Protein (PTHrP) Analog
Rank Ligand (RANKL) Inhibitor
By Route of Administration
Oral
Injectable
Others
By Distribution Channel
Hospitals Pharmacies
Online Pharmacies
Retail Pharmacies
By Country
North Africa
Central Africa
South Africa
Company Profiles
Merck & Co. *
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
Eli Lilly
Procter & Gamble
Enzo Biochem, Inc.
Sanofi-Aventis
Novartis
Wyeth
Roche.
GlaxoSmithKline
UCB
Amgen
BeiGene Co., Ltd.
Bone Biologics
Teijin Pharma Limited
JHL Biotech Inc.
Keros Therapeutics
Taro Pharmaceuticals Inc.
“*” marked represents similar segmentation in other categories in the respective section.